Index

abobotulinumtoxinA (Dysport®/Azzalure®) 5, 65–77, 137
action halo measurement 114–16
chest 271
comparisons with other BoNTA formulations 44, 66, 68, 69
dimpled chin 270
face lifting 270–271
forehead 73, 153, 154–7, 158, 267
gingival smile 269
glabellar lines 125, 133, 134, 135, 136, 137, 265
hyperhidrosis 227–8, 303, 304, 306, 307–8, 308, 309, 310
Marionette lines 270
microinjections in upper face 265
nasal wrinkles 269
neck 205, 206, 207, 208, 271
patient selection 122
periorbital 267
reconstitution 110, 112, 113, 136
topical applications 321
accessory proteins 37–8, 66
“accordion wrinkles” 203, 209
action halo 110
measurement 114–15, 116–17
additives, effects on migration and action halo 116–17
adjunctive therapy see combination therapy
adverse events see complications
aesthetics and cosmetics 5–6
BoNTA 70, 71–5, 85–90, 135
ethnicity and 277–81
BoNTB 56–8
brow muscles and 20
ethnicity and 277–81
face muscles 25
history 3
natural look 263–73
neuromodulators and their aesthetic targets 346–8
newer agents 98–106
affect and mood, modulating 345–56
African Americans and black people 275, 276, 277, 278, 279
aging 199–202
ethnicity and 275, 276, 277, 279, 280, 281
forehead 150–1
neck 199–202, 203–4
orbital aperture 34
perioral area, severity scales 193
skin 13–14, 199
aldehydes, axillary
hyperhidrosis 288
allergic and hypersensitivity reactions 135, 223
alpha motor neurons 42
aluminium chloride 287–8
anaesthesia see intravenous regional anesthesia;
nerve block; vibratory anesthesia
analgiesic, BoNTA as 329–32
anatomy 13–36
brow 18–21, 22, 148, 166, 167, 361
forehead 148–50, 361
glabellar 137–8
lower leg 185–6
masseter muscle 178
neck 199–202
periocular area 166–9
ANT-1207 (from Anterios) 106, 319, 326
anticholinergics in
hyperhidrosis systemic 288, 303
topical 288
antigenicity see immunogenicity
antiperspirants 287–8, 302–3
antiretroviral drug-related lipodystrophy 218
apocrine glands 286
Index

apocrine glands 286
“apple dumpling (dimpled) chin” 194–5, 270–1
arteries, facial 17
arthritic joint pain 331
Asians 276, 277, 278
counting 276, 280
assessment (pretreatment) see pretreatment preparation
asymmetry (facial) 213–20
correction 213–20, 268–9
forehead lines and 154
atrial fibrillation 339
atrophy, neck 199, 201
autistic children 353
axonal transport, retrograde 43
Azzalure 5, 65, 66, 263
B beauty enhancement 263–73
benign familial pemphigus (Hailey–Hailey disease) 291, 334
Bier’s block see intravenous regional anesthesia
biological weapons 2
bite force in masseter strength quantification 184–5
black people incl. African Americans 275, 276, 277, 278, 279
blepharoplasty 165, 217, 254, 264
blepharoptosis see ptosis
blepharospasm 98, 174
blood supply (vasculature), facial 17
BoCouture see incobotulinumtoxinA
bones, craniofacial 33–4
BoNTA and BoNTB see type A (neuro)toxin; type B (neuro)toxin
Botox® see onabotulinumtoxinA
Botox Cosmetic® see onabotulinumtoxinA
Botulax 98, 103
botulism 1, 2, 3
clinical 43
botulism-like syndrome 223
brain, BoNTA migration to 352–3
breast cancer and reconstruction with implants 332
breast-feeding and lactation 124, 135, 159
broadband light therapy 238–41
brow (eyebrow) 18–21, 165–76
anatomy 18–21, 22, 148, 166, 167, 361
contour/shape changing (contouring/shaping) 173, 236, 268
ethnicity and 276, 278
depressors 18, 20, 137–8
elevators 18, 20
females vs. male 19, 361
lateral lift/elevation 73–4, 127
ptosis see ptosis
tattoos 264
BTX-A and BTX-B see type A (neuro)toxin; type B (neuro)toxin
buccinator 29, 201
bullous dermatosis, linear IgA (LABD) 339
“bunny lines” (nasal wrinkles) 24, 25, 174–5, 225, 269, 348
cancer
breast 332
skin 253–8, 338
“canine smile” 28
canthal angle, lateral ethnicity and 276, 278, 279
canthal lines lateral see crow’s feet
medial 277
capsaicin 329, 332–3
carbon dioxide (CO₂) laser 322
hyperhidrosis 289
resurfacing 241
cervical arteries, external and internal 17
Carruthers, Dr. Jean 3
cautions see contraindications
central-fan pattern (lateral canthus) 172
cervical dystonia 42, 55
BoNTA 79, 159, 223
BoNTB 58
cervical wrinkles, horizontal 202–3, 206
CGRP’s (calcitonin gene-related peptides) 42, 329, 330, 331, 336
cheek complications affecting 227
fat compartments 15, 15–16
chemabrasion (manual) 245
chemical peels 2445
chemodenervation see denervation
children autism 353
granulosis rubra nasi 334
palmar hyperhidrosis 307
parotid duct injury 338
chin 128
complications affecting 227
dimpling 194–5, 270–1
ChinaTox 98, 105
cromhidrosis 309–10
Index

historical perspectives  3–5
skin  276, 277, 278, 329–43
cancer  253–8, 338
Clostridium botulinum  2, 3, 37
serotypes see serotypes
cold-induced analgesia see cryoanalgesia; ice
color (skin)  275–83
combination/adjunctive therapy  7, 233–51
face lifting  270–271
glabellar lines  233–6, 271
lower face  237–8, 270
neck and chest  271
periorbital lines  267
comissures, oral  75, 195–6
compensatory hyperhidrosis  303, 310, 335
complexing proteins, BoNTAs and freedom from  79–80, 122, 133, 134–5
implications  81–4
complications (and adverse events/side effects)  142, 218, 221–31, 362–4
beauty enhancement  266, 269, 270
BoNTA  59, 60, 142, 160–1, 362–4
lower face contouring  184–5
lower leg contouring  187–9
neck rejuvenation  209
BoNTB  60, 223
minor common  222–3
PurTox®  101–2
reconstitution and  111
severe and systemic  135, 223
site-specific  223–8
forehead  159–61, 223
computed tomography (CT), masseter hypertrophy measurement  181
connective tissue growth factors and hypertrophic scars  260
consensus conferences  71, 122
consent  122, 140, 152, 154
contouring and (re)shaping brow  173, 236, 267–268
brow see brow
ethnicity and  280
lower face  74–5, 177–85, 189
lower leg  185–9, 281
in masseter hypertrophy  217, 280
contraindications/cautions/avoidance BoNTA  123–4, 135, 159–61
drugs (other than toxins)  159, 222
forehead  159–61
periocular area  165
lower lid treatment  267
corrugator supercilli  20, 53, 138, 277, 338
BoNTA vs BoNTB injection  57, 58
cosmeceuticals  244–5
cosmetics see aesthetics and cosmetics
craniofacial hyperhidrosis  308
craniofacial shape and ethnicity  177
craniofacial skeleton  33–4
Croma Pharma and Hugel's Botulax  98, 103
crow's feet (lateral canthal/orbicular lines; LCLs)  5, 22, 59, 60, 70, 74, 89, 98–9, 106, 117, 126, 126–7, 167–8, 171–2, 173, 267, 279–80, 317, 319, 323, 324, 361
BoNTAs  89, 359, 361
ethnicity and  279–80
newer formulations  98–9, 319, 322, 323, 324, 326
combination (nonsurgical) therapy  236, 239, 242, 247
complications  226
cryoanalgesia (cold-induced analgesia) in palmar hyperhidrosis  304, 305
see also ice
CTGF (connective tissue growth factors) and hypertrophic scars  260
d
Daeroong Pharmaceutical Company  97–8
Darier's disease  334–5
darker skin  275–83
daxibotulinumtoxinA for injection (RT002)  106
for topical use (RT001)  105–6, 319–20, 324–6, 326
depression  338, 348–9
depressor(s)
brow  18, 20, 137–8
lip  18, 27, 29–31
depressor anguili oris (DAO)  16, 27, 29–31, 201, 216, 270
complications involving  227
Index

depressor anguli oris (DAO)
(Continued)
marionette lines and 29, 270
mouth frown and 195–6
neck rejuvenation and 201, 208
synkinesis and 216
depressor labii inferioris (DLI)
17, 27, 30–1, 201
chin dimpling and 194, 195
complications involving 227
mouth frown and 195, 196
neck rejuvenation and 201, 208
depressor nasi septi 25–6
depressor supercilii 138
dermal–epidermal junction and wrinkles 14
dermatochalasis 150, 153, 159
dermatology see skin
diffusion 110, 114–17, 155, 209–10, 221–2
BoNTA 70, 71, 155, 156, 158
forehead 155, 156
BoNTBs 56, 83
definition 110
risks of deep diffusion 209–10
in neck rejuvenation 205, 209–10
in periorbital treatment 226
see also migration
digital ischemia 336
dilution 109–10, 135–6
definition 109–10
forehead patients 156
glabellar patients 134, 135
types of diluents
FDA-approved 111
injection pain and 112–13
volume of (volume of
reconstitution) 113, 134, 135
dimpling of chin 194–5, 270–1
dissociation, incobotulinumtoxinA 81
“Doctor Spock brow” 18, 73, 160
dosing (for facial rhytides) 136
BoNTA 71, 265–71, 360
chest 271
forehead 153, 160–1, 267–8
glabella 136–7, 265
hyperhidrosis 290
lower face contouring 182, 183, 185
neck 205, 206, 207, 208, 271
periocular/periorbital 171, 172, 173, 174, 266–7
perioral wrinkles 269–270
BoNTB 58
hyperhidrosis 290–1
excessive see overdose
drugs (pharmaceuticals other than botulinum toxin)
contraindicated/cautions with 159, 222
hyperhidrosis 302–3
axillary 287–8
interactions 135
neuromuscular junction 124
duration of action/effects 141
incobotulinumtoxinA 81–2
DWP-450 (Nabota)Nabota 98, 103
dynamic expression lines, neck 14, 203
dyshidrotic Eczema 333
dysphagia 223
Dysport® see abobotulinumtoxinA
eccrine glands 286, 299, 300
hidrocystomas 335
non-botulinum treatment
288, 289, 303
eczema, dyshidrotic 333
ejaculation, premature 339
electrical muscle stimulation 245–6
elevators
brow 18, 20
lip 18, 26–9, 31
gummy smile and 196
emotion (facial)
emotional contagion 349–50, 351
facial display 350, 352, 353
indicators 346–8
endoscopic sympathectomy in
hyperhidrosis 289–90, 303, 309
epicanthal (superior palpebral) fold, lack in Asians 276
epicondylitis, lateral 331
epidermal–dermal junction and wrinkles 14
epidermolysis bullosa simplex (EBS)-Weber–Cockayne (WC) type 334–5
epinephrine (adrenaline)
as additive 116–17
sweating and sweat glands and 286, 299
erbium dual mode laser resurfacing 242
ethnicity and race
craniofacial shape and 177
skin color and 275–83
European studies
abobotulinumtoxinA 67, 71
incobotulinumtoxinA 98–9
onabotulinumtoxinA 86
Index

Page dimensions: 612.0x792.0

evaluation (pretreatment) see pretreatment
examination see pretreatment
exocytosis of neurotransmitters 37, 39, 41, 42
experimentation on humans 2–3
expression (facial) 345, 346, 348, 349, 350–3
emotion see emotion
mood affected by 338, 353
musculature (MFE) 17–32, 346–8
attenuation of action 348
neuropsychiatric disorders and 349
relaxation with BoNTA 348
negative, reducing/attenuation 338, 353
extensor digitorum brevis (EDB) 82, 85
eye
ethnicity and shapes of 276
region around see periorbital/periocular region
eyebrow see brow
eyelids 127, 166–7
anatomy 166–7
asymmetric/drooping 217
dermatochalasis 150, 153, 159
evaluation 125, 166–7
ptosis see ptosis
treatment 127
wrinkles/lines 127, 267
see also entries under blepharo-
f

contouring/shaping see contouring and shaping
emotional display 350, 352, 353
expression see expression
fat compartments 14–16
feedback hypothesis 338, 349–52, 353
flushing (persistent) 335–6
hyperhidrosis 308
lifting 271
lines and wrinkles see rhytides
in masseter hypertrophy, reshaping 217
mimicry hypothesis 349–50, 352, 353
nerve supply 16–17
reconstructive surgery 253–8, 337
rejuvenation/sculpting 191
adjunctive therapy 6
rhytides/wrinkles/lines see rhytides
scars see scars
skeleton 33–4
vasculature 17
see also lower face; midface; upper face
Facial Clinimetric Evaluation (FaCE) scale is 213
facial nerve 16–17, 150
aberrant regeneration after injury 215
weakness (paresis) and paralysis 213–20
failure of treatment 142
antibodies and 83–4, 142, 185, 189
fat compartments, facial 14–16
FDA see Food and Drug Administration
female forehead and brow anatomy 19, 361
fibroblasts and pathogenic scars 259–60, 337
fillers 233–8
5-fluorouracil, keloids 259
flushing, persistent facial 335–6
Food and Drug Administration (FDA) 2, 5, 44, 53
BoNTA 53, 65, 121, 122, 124, 317, 329, 357
forehead 147–64
aging and 150–1
anatomy 148–50, 361
complications 159–61, 223–4
fat compartments 14–15
wound healing of surgical scars 254
wrinkles/lines 72–3, 125–6, 147–64, 267–9
administration of toxin 158–9
BoNTA 72–3, 89–90, 114, 115, 125–6, 147–64, 278
BoNTB 56, 115
contraindications 159–61
dose selection 154–7
horizontal 149, 150, 151, 153, 157, 267–9
key points of technique 159
patient approaches 141–4
formulations 5
beauty enhancement 263
BoNTA see type A (neuro)toxin
BoNTB 5, 55
topical 319
frequency of glabellar treatment 142
Frey’s syndrome 308–9
frontal bone 20, 22, 23
frontalis muscle 16, 19–20, 59, 126, 149, 153, 267–8, 363
frown

frown glabellar lines see glabellar lines
mouth see mouth
Index

“frozen” look 152, 160, 263, 265, 268
“full denture smile” 28
full-fan pattern (lateral canthus) 172
future directions (incl. newer toxins and BoNTA) 7, 97–107
dermatology 329–43
hyperhidrosis 310
neuropsychiatry 345, 353
topical BoNTA 326

g
Galderma’s “liquid” toxin 105
gastrocnemius 185, 186, 187
ethnicity and 281
gender and forehead and brow anatomy 19, 361
gingival (gummy) smile 28, 196–7, 217, 269
glabellar administration for forehead patients 157
too broad or high 160
glabellar lines/wrinkles/rhytids 71–2, 124–5, 133–45, 265–6, 359, 360–1
anatomical considerations 137–8
BoNTA (abobotulinumtoxinA) 67, 68, 69–70, 71–2, 85–9, 124–5, 133–45, 265–6, 359, 360–1, 363
BoNTB 56, 57, 58, 59
combination therapy 233–6, 271
complications of treatment 224–5
headaches 225, 336, 363
newer toxins 98, 99, 100, 102
“golf ball (dimpled) chin” 194–5, 270–1
gravimetric testing of hyperhidrosis 286, 301–2
gummy smile 28, 196–7, 217, 269

gustatory sweating 308–9

h
Hailey–Hailey disease 291, 334
hairline, receding 148, 158
halo of action see action halo hands
ischemic digits 336
palmar hyperhidrosis 116, 227–8, 290, 293, 304–7, 335, 362
headaches 363
in glabellar treatment 225, 336, 363
migraine 42, 331–2
healing, wound see wound healing
heat treatment, hyperhidrosis 289
heavy chains 4, 39–40, 54, 55, 65, 79
hematoma 126, 222
Hengli/Prosigne 182, 264, 317
herpes simplex virus 222
herpes zoster 222, 330
hidrocystomas, eccrine 335
highly active antiretroviral drug (HAART)-related lipodystrophy 218
histamine and pruritus 332
histology
skin color and 276
wrinkles 13–14
history 1–3
neck rejuvenation 199
history-taking 122–3
HIV see human immunodeficiency virus
horizontal (transverse)
wrinkles
cervical 202–3, 206
forehead 149, 150, 151, 153, 157, 267–9

House–Brackmann scale 213, 214
Hugel’s Botulax 98, 103
human experimentation 2–3
human immunodeficiency virus (HIV)
HAART-associated lipodystrophy 218
TAT 319
hyaluronic acid (HA) fillers 233, 234–5, 236, 238, 267
hyaluronidase 117, 236
hyperhidrosis 106, 227–8, 285–315, 333–9, 362
compensatory 303, 310, 335
complications of treatment 227–8
dermatologic conditions and 333–9
diagnosis/measurement 287–8, 301–2
focal (general aspects) 285, 289–90
primary 286, 300, 302
unilateral 310
generalized 285, 299–300, 301
palmar 116, 227–8, 290, 293, 304–7, 335, 362
plantar 288, 307–8, 362, 364
quality of life 286, 287, 300–1
severity 287, 300

treatments 287–93, 302–10
hyperkinetic/hyperfunctional facial lines 5, 6, 19, 58, 74, 147, 151
hypersensitivity and allergic reactions 135, 223
hypertrophic osteoarthropathy, primary 336–7
hypertrophic scars 258–60, 337
hypertrophy
  benign prostatic (benign prostatic enlargement) 338–9
calf 185, 186, 187, 189
electrical stimulation-induced 245–6
masseter see masseter
hypoglossal–facial nerve anastomosis 214–15
hypohidrosis and anhidrosis
  action halo measured by extent of 114–15
  forehead 156
  palmar 304
  progressive segmental 310

i

ice and pressure (with injections)
  palmar hyperhidrosis 306
  plantar hyperhidrosis 307–8
imaging, masseter
  hypertrophy measurement 181
immunogenicity/antigenicity
  (antibodies to toxin; immune resistance) 43–4, 83–4, 134–5, 218
  BoNTA 43–4, 55, 67, 68, 83–4, 189
immunoglobulin A bullous dermatosis, linear (LABD) 339
inactive neurotoxin in
  incobotulinumtoxinA 80–4
incobotulinumtoxinA
  (BoCouture/Xeomin®/XU) 5, 65, 79–95, 97, 98–101, 137
action halo measurement 114–16
  aesthetic applications 85–90
  chest 271
  comparisons with other type
    A formulations 44, 66, 68, 69
    potency 84–5
  complexing proteins and freedom from them 79–84
  face lifting 270–271
  forehead 153, 154–5, 157, 267
gingival smile 269
  glabellar lines 125, 133, 134, 135, 136–7, 137, 265
  hyperhidrosis 303
  inactive 80–4
  manufacture and production 79–80
  Marionette lines 270
  nasal wrinkles 269
  neck 205, 206, 207, 208, 209, 271
  patient selection 122
  periocular/peri orbital area 169, 172, 267
  perioral area 193, 194, 195, 196, 197, 269–270
  reconstitution 110–11, 136
  indications
    abobotulinumtoxinA 44
    lower face 75
    upper face 71
    FDA-approved 44
    infections, injection site-related 222
    informed consent 122, 140, 152, 154
    injection (administration) 140
    hyperhidrosis
      axillary 291–2
      facial 308, 309
      palmar 304–7
      plantar 307–8
      pain from, diluent type and 112–13
      repeated see repeated treatments

syringes and needles for see syringes and needles
  techniques and points (sites) 265–71
  beauty enhancement 265–71
  complications 222–3
  forehead 153, 157–8, 267–9
  glabellar 140, 265–6
  hyperhidrosis, see subheading above
  lower face contouring 179–80
  lower leg contouring 186
  periocular/peri orbital 172–5, 266–7
  perioral 192–3, 195–6, 269–70
too deep, in neck rejuvenation 209–210

innervation see nerve supply
  intense pulsed light (IPL) 238–41, 259
International Board Botulinum Toxin 71
  intervals between glabellar treatments 142
  intravenous regional anesthesia (IVRA; Bier's block) palmar hyperhidrosis 305
  plantar hyperhidrosis 307
  iontophoresis 322
  in hyperhidrosis 288, 303
  ischemic digits 336
  itching (pruritus) 332–3

j

jaw 128–9
see also mandible
  joint pain, arthritic 331
  jowl fat compartment 16

k

keloidal scars 258–60
  keratosis follicularis 334–5
Index

Kerner, Dr. Justinus
“Wüstst” 1

lactation and breast-feeding
124, 135, 159
lagophthalmos 165, 170
Langer’s lines 254
laser use 322
hyperhidrosis 289
for resurfacing 241–5
vertical lip lines 192
lateral canthal angle (palpebral fissure inclination) and ethnicity 276, 278, 279
lateral canthal lines see crow’s feet
lateral epicondylitis 331
lateral eyebrow lift/elevation 73–4, 127
Latin Americans 275, 276
LD\textsubscript{50} (median lethal dose) 44, 45, 68–9, 154
leg (lower), contouring 185–9, 281
lethal dose, median (LD\textsubscript{50}) 44, 45, 68–9, 154
levator anguli oris 27, 29, 216
gummy smile and 196
levator labii superioris, gummy smile and 196–7
levator labii superioris alaeque nasi 27, 28
gummy smile and 196–7
levator palpebral superioris 23, 24, 72, 74
lidocaine, hyperhidrosis 291
light-based therapies 238–41
light chains 4, 39, 40, 41, 42, 55, 79
linear immunoglobulin A bullous dermatosis (LABD) 339
lines of aging see rhytides
lines of Langer 254
lip 26–32, 192–4
complications of treatment 226–7
depressors 18, 27, 29–31
elevators see elevators
lines 127, 192–4, 226–7
ethnicity and 280
vermillion border 127, 227, 245, 280
lipodystrophy disorders 185, 218
liquid formulations of BoNTB 55–6
lower face
beauty enhancement 269–71
combination therapy 237–8, 270
complications 218, 363
contouring 74–5, 177–85, 189
ethnicity and 280
lower leg contouring 185–9, 281

magnetic resonance imaging (MRI), masseter hypertrophy measurement 181
malar fat compartments 15
male forehead anatomy 19, 361
mandible anatomy 33–4, 178
contouring 177–8
ethnicity and 280, 281
masseter injections and their effects on 184
in neck rejuvenation, loss of definition of edge 206–8, 209
see also jaw
marionette lines 29–30, 270
maser treatment and 129, 184
maxilla 33
mechanism (mode) of action 38–43, 134, 332
historical perspectives 3–4
neuropsychiatric disorders 349
sensory 42–3
wound healing 337
medical applications see clinical applications
Meditoxin/Neuronox 98, 103–5, 264, 317, 337
melanin 276
melanosomes 275–6
men’s (male) forehead and brow anatomy 19, 361
mental crease/fold 194–5
complications 194–5, 227
see also chin
mentalis 27, 31, 270
chin dimpling and 194–5, 270
complications involving 227
marionette lines and 270
“Mephisto brow” 18, 73, 160, 206
Merz Aesthetics scale 89, 152
Mexicans and skin color 276
microwave treatment, hyperhidrosis 289
midface
beauty enhancement 268–71
expression musculature 26–32
migraine 42, 331–2
migraine/spread 110, 114–17
BoNTA 82–3, 114, 115
to brain 352–3

mastectomy, reconstruction after 332
mastication (and muscles of mastication) 29, 33, 178, 184
masseter treatment and 129, 184

melanin 276
melanosomes 275–6
men’s (male) forehead and brow anatomy 19, 361
mental crease/fold 194–5
complications 194–5, 227
see also chin
mentalis 27, 31, 270
chin dimpling and 194–5, 270
complications involving 227
marionette lines and 270
“Mephisto brow” 18, 73, 160, 206
Merz Aesthetics scale 89, 152
Mexicans and skin color 276
microwave treatment, hyperhidrosis 289
midface
beauty enhancement 268–71
expression musculature 26–32
migraine 42, 331–2
migraine/spread 110, 114–17
BoNTA 82–3, 114, 115
to brain 352–3
incobotulinumtoxinA
82–3, 114, 115
forehead 155
mimethery in synkinesis
216
mimicry, facial 349–50, 352, 353
minimal skin excision in
hyperhidrosis 289
Minor’s (starch–iodine) test
287, 301, 303, 307, 308, 309
MiraDry 289
mirrorneurons 349, 352
mode of action see mechanism
of action
Moebiussyndrome 352
Mohsmicrographic surgery
255, 338
“M ona Lisa smile” 28
monopolar radiofrequency
energy 245
mood and affect, modulating
345–56
motorneurons 41, 42, 43
mouth
angle of 128
downturned corners (mouth
frown) 195–6
ethnicity and 280
gummy smile treatment
and movements of 269
see also oral commissures;
perioral region
Mu(e)ller’s muscle 73, 74, 218, 225
multiple treatments see
repeated treatments
muscles
electrical stimulation
245–6
facial expression see
expression
forehead 149, 153
hypertrophy see
hypertrophy
masticatory see mastication
neck 200–2
Myobloc[O] see type B
(neuro)toxin
n
Nabota (DW-450) 98, 103
nasal bones 33, 138
nasal flare 24
nasal wrinkles (“bunny lines”)
24, 25, 174–5, 225, 269, 348
nasalis 24, 25, 175, 269
nasolabial fat compartments
15
natural look 263–73
NDSTM platform delivery
technology 319
neck 129, 199–211, 271
aging 199–202, 203–4
anatomy 199–202
needles see syringes and
needles
“Nefertiti neck lift” 33, 204
nerve blocks
palmar hyperhidrosis 305, 307
plantar hyperhidrosis 307
nerve supply/innervation
face 16–17
forehead 149–50
sympathetic 299
NeuroBloc see type B
(neuro)toxin
neuromodulators,
psychosocial
implications 345–56
neuromuscular junction 3, 4,
41, 42, 66, 81
adverse events affecting
223
pharmaceutical agents
(other than BoNT)
interacting at 124
pre-existing disorders 135
Neuronox 98, 103–5, 264,
317, 337
neuropeptides 42
pain and 329, 330, 332
pruritus and 332
psoriasis and 334
neuropsychiatric disorders
338, 345–56
neurotransmitters 3, 4, 39,
40, 43, 45
exocytosis 37, 39, 41, 42
sweating and 299
newer toxins and applications
see future directions
“Nicholson brow” 18, 24
nose, see entries under nasal
O
onabotulinumtoxinA (Botox®/
BotoxCosmetic®/BU/
Vistabel®/Vistabex)
5, 65, 136–7, 357–68
action halo measurement
114–16
chest 271
comparisons with other
formulations 44, 68,
69, 98–101
potency 84–5
dimpled chin 270
epinephrine added to, in
axillary hyperhidrosis
117
face lifting 270–271
forehead 73, 153, 154–7,
158, 159, 160, 267–8
gingival smile 269
glabellar frownlines 85–8,
125, 133, 134, 135,
136–7, 265
hyperhidrosis 303, 304,
307, 308, 309, 310
axillary 227–8, 290, 291,
292, 293, 357–8, 362
keloids 258
lower face contouring 179
Marionette lines 270
microinjections in upper
face 265
nasal wrinkles 269
neck 205, 206, 207, 208,
209, 271
patient selection 122
periocular/periorbital area
168–9, 267, 270
Index

onabotulinumtoxinA (Continued)
crow’s feet 89, 127, 359, 361
eyelids 127
perioral area 193, 194, 195, 196, 197
reconstitution 110, 111–12, 113, 136, 358
storage and preparation 358–9
surgical wounds 254, 255–8
onset of action/response 141
incobotulinumtoxinA 81–2
ophthalmic nerve 149–50
oral commissures 75, 195–6
see also mouth; perioral region
orbicularis oculi 5, 16, 19, 20, 22–3, 138, 361–2
divisions/portions/segments 22–3, 167
forehead treatment and 224
glabellar treatment and 140
periorcular area treatment and 167, 168, 170–1, 173, 174, 361–2
orbicularis oris 5, 16, 17, 25, 26, 27, 28, 29, 31, 192, 237, 280
gummy smiles and 196
orbit aging 34
fat compartments 15
injections below 72, 218
orbicularis oculi orbital portion 22, 167, 173
see also periorbital/periorcular region
osteoaarthropy, primary hypertrophic 336–7
overdose 218
forehead 160
lower face 74
neck 209
periorcular 218
perioral 191, 192, 193, 195, 218
p
pachydermoperiostosis
pachydermia 336–7
pain alleviation 329–32
injection diluent type and 112–13
hyperhidrosis treatment 291
periorcular 173
periorbital/periocular region
palm hyperhidrosis 116, 227–8, 290, 293, 304–7, 335, 362
palpebral fissure inclination (lateral canthal angle) and ethnicity 276, 278, 279
palpebral fold, superior, lack in Asians 276
palpebral portion/segment of orbicularis oculi 22, 74
parotid (gland and duct) Frey’s syndrome and 335
skin cancer involving 338
patient pretreatment preparation and assessment see pretreatment preparation/assessment/evaluation satisfaction with onabotulinumtoxinA use 364
selection see selection ‘peach pit (dimpled) chin’ 194–5, 270–1
peculiaris major 271
pediatrics see children
pemphigus, benign familial (Hailey–Hailey disease) 291, 334
penile retraction 339
peptide transporters for topical BoNTA applications 319–23
axillary hyperhidrosis 293, 322
periocular region see periorbital/periocular region
periorbital region 127–8, 191–8, 269–270
lines 191–3, 270
overdose 191, 192, 193, 195, 218
periorbital/periorcular region 165–76, 266–7
excessive toxin dose 218
lines, BoNTA 89–90, 165–76, 225–6, 266–7, 361–2
complications 225–6
ethnicity and 278–9
see also crow’s feet
perspiration see sweating pharmacology 44–5
BoNTB 53–5
see also drugs
photodamage and photoaging light-based therapies 238
neck wrinkles 202
photographs 140
masseter hypertrophy, serial 181–2, 183
physical examination see pretreatment preparation/assessment/evaluation
physiotherapy in synkinesis 216
pigmentation disorders 336
pigmented skin 275–83
piloleiomyomas, multiple cutaneous 331
plantar hyperhidrosis 288, 307–8, 362, 364
platysma 27, 32–3, 200–1, 205–6
aging 201
bands 75, 90, 129, 201, 202, 204–6
complications of treatment 227
function 201
poisoning, sausage 1–2
poly-L-lactic acid 218, 238
posttreatment care 141
potency (and its assessment) 44, 45, 56
BoNTAs 84–5
pregnancy 124, 135, 159
premature ejaculation 339
preparation of patient 139–42
preseptal portion/segment of orbicularis oculi 22–3, 167, 174
pretarsal portion/segment of orbicularis oculi 20, 22–3, 127, 165, 167, 170, 172, 174
pretreatment preparation/assessment/evaluation (incl. examination) 122–3
beauty enhancement 264–5
facial nerve impairment 213
in synkinesis 216
forehead treatment 151–4
glabellar treatment 139–40
lower face contouring 178
periocular treatment 169–72
procerus 20, 21, 124, 138, 361
injection 57, 58, 72, 86, 140, 277, 337, 338
Prosigne/Hengli 182, 264, 317
prostatic enlargement, benign 338–9
pruritus 332–3
psoriasis, inverse 333–4
psychosocial implications of neuromodulators 345–56
ptosis, eyelid (blepharoptosis)/eyebrow 166, 236, 278
treatment-related 67, 73, 125, 142, 160, 166, 224, 224–5, 225, 265, 278, 308, 363
pulsed light, intense (IPL) 238–41, 259
PurTox® 97, 101–3, 106
q
quality of life (QoL) with hyperhidrosis 286, 287, 300–1
r
race see ethnicity
radiofrequency energy 245
Raynaud's phenomenon 336
reconstitution 109, 110–13, 135–6, 263–4
definition 109
reconstitution 110, 111–12, 113, 136, 358–9
reconstructive facial surgery 253–8, 337
rejuvenation, facial see face
repeated (multiple) treatments
rhytides/wrinkles/lines (face) 13–14, 357–68
action halo measured by reduction in 114
BoNTA 85–90, 367–8
upper face 71–4, 89–90, 277–8, 363, 364
BoNTB 56–8
defining 13
hyperfunctional/
hyperkinetic 5, 6, 19, 58, 74, 147, 151
nasal (“bunny lines”) 24, 25, 174–5, 225, 269, 348
neck 199, 202–3, 271
newer agents 98–106
perioral 191–3, 270
lip see lip
upper face BoNTA 71–4, 89–90, 277–8, 363, 364
ethnicity and 277–9
forehead see forehead
perioral see periorbital/periorcular see periorbital/periorcular region
rimabotulinumtoxinB see type B (neuro)toxin
risorius 29, 201–2, 216
Ross syndrome 310
RT001 (daxibotulinumtoxinA for topical use) 105–6, 319–20, 324–6, 326
RT002 (daxibotulinumtoxinA for injection) 106
s
safety 142
onabotulinumtoxinA 362–4
stored solutions 112
see also complications
sagging in neck 199, 202, 203, 205, 206
satisfaction (patient) with onabotulinumtoxinA use 364
sauage poisoning 1–2
scars hypertrophic 258–60, 337
keloidal 258–60
reconstructive surgery-related 253–6
Scott, Dr. Alan 2
Index

selection (patient) 121–31
forehead treatment 151–4
neck treatment 208–9
periocular treatment 169–72
selection of patient see patient
sensory innervation of forehead 149–50
sensory mechanisms of action 42–3
serotypes, C. botulinum 2, 3, 37, 38, 55, 56, 60, 133
immunogenicity and 43
shaping see contouring
Siax (Neuronox) 98, 103–5, 264, 317, 337
side effects see complications
skeleton, craniofacial 33–4
skin
anatomy in aging vs youthful skin 13–14
color 275–83
disorders (dermatology) 329–43, 357–68
BoNTA 329–43, 357–68
cancer 253–8, 338
forehead 148–9
minimal excision in hyperhidrosis 289
neck 199–203
toxin delivery through see transcutaneous/
transepidermal delivery
smiling
asymmetry 216–17
gummy/gingival smile 28, 196–7, 217, 269
muscles and 25, 26, 27, 28, 30, 31
types of smile 28
SNAP-25 (synaptosomal associated protein-25) 4, 37, 40, 41, 55, 65, 321, 352
SNARE complex 40, 41, 42, 43, 55
soft tissue fillers (for augmentation) 233–8
sole (plantar surface), hyperhidrosis 288, 307–8, 362, 364
soleus 185, 186, 187
solutions
stored see storage
vigorous mixing 112
see also reconstitution
Snyepwood units 66
sphincteric musculature, orbicularis oris
“Spock brow” 18, 73, 160
spread see diffusion; migration
stability, incobotulinumtoxinA 81
starch–iodine (Minor’s) test 287, 301, 303, 307, 308, 309
sterility, stored solutions 112
storage (of solutions) 136, 263–4
effectiveness of stored solutions 111–12
onabotulinumtoxinA 358–9
safety and sterility 112
vigorous mixing of stored solutions 112
stratum corneum 317, 318, 321–2
structure
botulinum toxin 37–41
facial, ethnicity and 276
Subcision® 266, 270
subcutaneous fat, neck 199
substance P 42, 329, 330, 332, 333, 336
superficial
musculoaponeurotic system (SMAS) 16, 32, 149
surgery
dermatologic 329–43
focal, in hyperhidrosis 288–9, 303
wound healing of surgical sites 253–8, 337
SV2 (synaptic vesicle 2) 39
swallowing difficulties 223
sweat glands 286
sweating (perspiration) 285, 299
abnormal see hyperhidrosis; hypohidrosis
action halo measured by extent of reduction in 114–15
anatomy and physiology/pathophysiology 286, 299
symmetry (importance and its assessment) 123, 265
chin 128
forehead/brow 125–6
lips 128
see also asymmetry
sympathetic nervous system 299
endoscopic sympathectomy in hyperhidrosis 289–90, 303, 309
synaptic vesicle 2 (SV2) 39
synaptobrevin (VAMP; vesicle-associated membrane protein) 4, 40, 55
synaptosomal associated protein-25 (SNAP-25) 4, 37, 40, 41, 55, 65, 321, 352
synkinesis 213, 215–16
assessment (incl. Synkinesis Assessment Questionnaire) 213, 215
syringes and needles 359–61
forehead patients 158
glabellar patients 136
hyperhidrosis
axillary 291–2
palmar 305, 306, 307
plantar 307
systemic adverse effects 223
in glabellar treatment 135
systemic agents in
hyperhidrosis 288, 303
TAT (trans-activator of transcription) 319
tattoos, brow 264
temperature and
incobotulinumtoxinA
stability 81
temporal-cheek fat
compartments
14–15, 15–16
temporal lift 127
temporalsis 25
tennis elbow 331
TGF-β1 (transforming growth
factor beta 1) and
keloids 259–60
therapeutic applications see
clinical applications
thoracoscopic (endoscopic
thoracic)
sympathectomy in
hyperhidrosis
289–90, 303, 309
tinnitus 339
topical treatment and agents
317–28
axillary hyperhidrosis
287–8, 322–3
daxibotulinumtoxinA
Topical Gel (RT001)
105–6, 319–20, 324–6,
326
touch-up treatment 123, 265
beauty enhancement 265
forehead 154, 160
glabellar lines 140, 266
nasal wrinkles 269
neck and chest 271
perioral 198
trans-activator of transcription
(TAT) 319
transcutaneous/
transepidermal delivery
317–26
axillary hyperhidrosis 292,
322–3
transforming growth factor
beta 1 (TGF-β1) and
keloids 259–60
transient receptor potential
vanilloid receptor 1
(TRPV1-receptors) 42–3, 329, 333, 336
peptide transporters see
transverse wrinkles see
horizontal wrinkles
treat-to-goal approach 152
TRPV1 (transient receptor
potential vanilloid)
receptors 42–3, 329, 333
“turkey neck” 199, 201, 202
type A (neuro)toxin (BTX-A;
BoNTA; BTA) 65–95, 121–64, 317–43
beauty enhancement 263–73
complexing proteins see
complexing proteins
consensus conferences 71, 122
dermatology 329–43,
357–68
diffusion and migration see
diffusion; migration
ethnicity and aesthetics and
277–81
FDA and 53, 65, 121, 122,
124, 317, 329, 357
forehead rhytides 72–3,
89–90, 125–6, 147–64,
278
formulations 5
comparisons between
various types 44, 68, 69
comparisons with type B
via action halo
measurement 115–16
see also specific
formulations/types
glabellar lines 67, 68,
69–70, 71–2, 85–9,
124–5, 133–45, 265–6,
359, 360–1, 363
hyperhidrosis 227–8,
290–3, 304–5, 307,
308, 309, 310
immunogenicity 43–4, 55,
67, 68, 83–4, 189
lower face contouring
74–5, 177–85, 189
mechanism of action 134
patient selection 121–31
perioral area 191–8,
269–70
potency 84–5
properties/mechanism of
action/clinical effects
3–4, 5
psychosocial implications of
neuromodulators and
345–56
scars of facial reconstructive
surgery 254, 254–5
keloidal and hypertrophic
258–60
topical 105–6, 317–28
type B (neuro)toxin (BoNT
type B; BoNTB;
rimabotulinumtoxinB;
Myobloc®; NeuroBloc®) 5,
53–77
action halo measurement
compared with type A
115–16
adverse events/
complications 56–8
formulations 5, 55–6
hyperhidrosis 227–8,
290–1, 310
properties/mechanism of
action/clinical effects
3–4, 53–77
reconstruction 111, 358–9
reconstructive surgery scars
255
treatment considerations
58
type E (neuro)toxin 41
Index

U
ulcer, healing 337
upper face
aesthetics
  beauty enhancement 265–9
  ethnicity and 277–80
expression musculature 18–24
lines see rhytides
upper-fan pattern (lateral canthus) 172

V
VAMP (vesicle-associated membrane protein; synaptobrevin) 4, 40, 55
van Ermengem; Emile Pierre 2
vanilloid receptor 1 (VR1) 329
vasculature, facial 17
vasoactive intestinal peptide (VIP) 332
veins, facial 17
vermillion border 127, 227, 245, 280
vertical lip lines 192–4, 280
vesicle-associated membrane protein (VAMP; synaptobrevin) 4, 40, 55
vibratory anesthesia and massage devices (in hyperhidrosis) 364
palmar hyperhidrosis 305–6
plantar hyperhidrosis 307
video-assisted thoracoscopic sympathectomy in hyperhidrosis 289–90
VIP (vasoactive intestinal peptide) 332
Vistabel® see onabotulinumtoxinA
Vistabex® see onabotulinumtoxinA
vitiligo 336
volume of dilution or reconstitution 113, 134, 135

W
warfare 2
Weber–Cockayne (WC)-type epidermolysis bullosa simplex 334–5
women’s (female) forehead and brow anatomy 19, 361
wound healing 337
surgical site 253–8, 337
wrinkles see rhytides

X
Xeomin® see incobotulinumtoxinA

Z
zygoma 33
zygomatic nerve 16–17
zygomaticus 15, 26, 27, 28, 29, 168, 171
gummy smile and injections and 196
126, 169, 216, 219, 226, 267